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Abstract
Background: A number of studies have found associations between dysbindin (DTNBP1) polymorphisms and 
schizophrenia. Recently we identified a DTNBP1 SNP (rs9370822) that is strongly associated with schizophrenia. 
Individuals diagnosed with schizophrenia were nearly three times as likely to carry the CC genotype compared to the 
AA genotype.
Methods: To investigate the importance of this SNP in the function of DTNBP1, a number of psychiatric conditions 
including addictive behaviours and anxiety disorders were analysed for association with rs9370822.
Results: The DTNBP1 polymorphism was significantly associated with post-traumatic stress disorder (PTSD) as well as 
nicotine and opiate dependence but not alcohol dependence. Individuals suffering PTSD were more than three times 
as likely to carry the CC genotype compared to the AA genotype. Individuals with nicotine or opiate dependence were 
more than twice as likely to carry the CC genotype compared to the AA genotype.
Conclusions: This study provides further support for the importance of DTNBP1 in psychiatric conditions and suggests 
that there is a common underlying molecular defect involving DTNBP1 that contributes to the development of several 
anxiety and addictive disorders that are generally recognised as separate clinical conditions. These disorders may 
actually be different expressions of a single metabolic pathway perturbation. As our participant numbers are limited 
our observations should be viewed with caution until they are independently replicated.
Background
Dystrobrevin binding protein 1 (DTNBP1) is a neuronal
protein that binds to alpha- and beta-dystrobrevin in
muscle and brain [1]. Association and functional studies
suggest a role for the DTNBP1  gene in schizophrenia.
Linkage studies first identified DTNBP1  as a region of
high schizophrenia susceptibility [2-4] and polymor-
phisms in DTNBP1 have since been identified to be asso-
ciated with schizophrenia [3,5,6]. Biologically, DTNBP1 is
a strong candidate for schizophrenia pathogenesis as it is
thought to play a pivotal role in regulating the gluta-
matergic system [7,8]. Glutamate hypofunction leads to
increased sensory flooding and changes in dopamine
concentration. Hence, glutamate receptor agonist drugs
are now used in the treatment of schizophrenia [9]. Func-
tional studies of DTNBP1 provide further evidence for its
role in schizophrenia aetiology. Reduced DTNBP1 mRNA
e x p r e s s i o n  i n  c e r e b r a l  c o rt e x  h as  bee n  as socia t ed  wi t h
risk haplotypes for schizophrenia [10]. Reduced DTNBP1
mRNA and protein expression has been found in the hip-
pocampal formation and dorsolateral prefrontal cortex of
schizophrenia patients [11-13]. Schizophrenia patients
showed reduced presynaptic DTNBP1 which was related
to glutamatergic alterations in intrinsic hippocampal for-
mation connections [11]. More recently, it has been
established that reductions in protein in the brains of
schizophrenia patients occurred in the dysbindin-1C iso-
form but not dysbindin-1A or -1B [14]. Studies also con-
cluded that dysbindin-1C in the human brain is
concentrated in the synapses [14]. Tang et al. [14] con-
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cluded that decreased dysbindin-1C in the dorsolateral
prefrontal cortex may induce NMDA receptor hypofunc-
tion in fast-spiking interneurons contributing to the cog-
nitive deficits of schizophrenia.
DTNBP1 is associated with other psychotic conditions.
Association with DTNBP1 was found with bipolar disor-
der but only in a small subgroup characterised by the
c o m p l i c a t i o n  o f  p s y c h o t i c  f e a t u r e s  d u r i n g  e p i s o d e s  o f
mood disturbance [15]. Methamphetamine psychosis is
clinically similar to schizophrenia [16,17] and a recent
study hypothesised that DTNBP1 may also be associated
with substance-induced psychoses [18]. Significant asso-
ciations with methamphetamine psychosis and DTNBP1
variation was identified in a case-control study [18].
The aim of this study was to examine whether DTNBP1
variation shows genetic association with a range of psy-
chiatric conditions, including schizophrenia, suggesting
that changes in metabolism related to variations in
DTNBP1 protein function underlies a common molecu-
lar defect in these conditions. A polymorphism in the
human dopamine D2 receptor (DRD2) (rs6277) has pre-
viously been found to be associated with a number of psy-
chiatric conditions or traits associated with
psychopathology. The DRD2  polymorphism was first
found to be associated with schizophrenia [19]. Since this
study rs6277 has also been found to be associated with
post-traumatic stress disorder (PTSD) [20], working
memory ability [21], impulsivity [22] and alcohol depen-
dence [23]. Like the DRD2  polymorphism, a common
polymorphism in DTNBP1  may be associated with a
range of psychiatric conditions. In a previous study, we
found a polymorphism in DTNBP1 (rs9370822) that was
strongly associated with schizophrenia [24]. It is also well
known that anxiety and addictive disorders are common
comorbidities of schizophrenia [25,26], so, to examine
the importance of this DTNBP1  SNP in addictive and
anxiety disorders, a number of psychiatric groups were
genotyped for rs9370822.
Methods
Subjects
Controls
The control group consisted of 250 unrelated Caucasians
(102 female and 148 male) with a mean age of 36.8 years
(s.d. ± 12.8 years). The control group consisted mostly of
medical and nursing staff recruited through hospitals,
and university students and academic staff. Formal
screening for psychological disorders was not undertaken
in the control population. As such the controls represent
an unselected control group.
Opiate dependence
A total of 120 unrelated Caucasian participants (50
female and 70 male) diagnosed as opiate dependent were
recruited for this study, all of whom were being assessed
for naltrexone treatment as outpatients of the Hospital
Alcohol and Drug Services Unit of the Royal Brisbane
and Women's Hospital. Participants had a mean age of
28.7 years of age. Approximately half of the participants
were being managed on methadone prior to detoxifica-
tion (47.2%) while the other half were on heroin (52.8%).
Those on methadone had a mean dose of 48.1 milligrams
(s.d. 30.5), with a range between 10-165 milligrams. The
mean age of onset of heroin use was 22.4 years of age (s.d.
5.14), with a range between 15-43 years. Mean number of
participant-reported detoxifications prior to this occa-
sion was 3.5 (s.d. 3.3), with a range between 0-16 detoxifi-
cations. Cannabis was the most commonly concurrently
used illicit substance reported by participants prior to
treatment (52.5% reported use), followed by amphet-
amines (14.9% reported use).
PTSD
A total of 127 unrelated male Caucasian patients diag-
nosed with PTSD using Diagnostic and Statistical Manual
of Mental Disorders-IV (DSM-IV) criteria were recruited
through the Greenslopes Private Hospital for the study.
All subjects were Vietnam combat veterans who had
served in the Australian Armed Forces with a mean age of
52.3 years (s.d. ± 6.1 years). None were being treated with
psychotropic medications. Patients were excluded from
the study if they had a diagnosis of psychosis, bipolar dis-
order, obsessive-compulsive disorder, or organic brain
syndrome including dementia. All subjects had sufficient
comprehension of English and could understand the
administered questionnaires. Patients were assessed for
PTSD by a consultant psychiatrist or a senior psychiatric
registrar using DSM-IV criteria. Furthermore, every
patient exceeded the clinical cut-off score of 94 on the
Mississippi Scale for combat-related PTSD [27]. Patient
clinical history and demographic data including ethnic
background were also obtained. After the procedure had
been fully explained, all participants provided written
i n f o r m e d  c o n s e n t .  T h e y  w e r e  a b l e  t o  t e r m i n a t e  t h e i r
involvement at any time during the interview without
prejudice. Institutional ethics approval was obtained
from the Greenslopes Private Hospital.
Alcohol dependence
A total of 231 unrelated Caucasian (47 female and 184
male) alcohol dependent subjects were recruited from
large public hospitals in Brisbane, Australia. The mean
age of the group was 42.1 years (s.d. ± 10.8 years). All sub-
jects were assessed by a clinical psychologist experienced
in drug and alcohol dependence and met DSM-IV criteria
of alcohol dependence disorder. All were inpatients and
represented a spectrum of severity with a significant pro-
portion (n = 65) of these patients being diagnosed with
two or more alcohol related medical conditions such as
pancreatitis, cirrhosis, hepatitis or peripheral neuropathy.
Alcohol dependent patients were excluded from the studyVoisey et al. Behavioral and Brain Functions 2010, 6:41
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if they had dementia, delirium, psychosis, or any other
condition that would affect their ability to provide
informed consent.
Nicotine dependence
A total of 147 (68 male, 79 female) unrelated Caucasians
with a mean age of 43.3 (s.d. ± 11.1 years) were recruited
for this study through hospital and media advertise-
ments. Participants were 18 years of age or older and had
smoked for at least three years and were generally healthy
despite currently smoking 15 cigarettes or more per day.
All were motivated to reduce smoking and had the goal of
eventual cessation. However, all participants had at least
one serious but unsuccessful attempt at quitting in the
previous 24 months. One hundred and thirty nine of the
participants were administered the Fagerstrom test for
nicotine dependence [28].
To minimise population stratification bias, both control
and clinical subjects were recruited in the Brisbane
region (a city of approximately 2 million inhabitants on
the East Coast of Australia) and all were of British or
European descent.
Ethics approval was obtained from all institutions
involved and each participant gave written informed con-
sent. This study was carried out in accordance with The
Code of Ethics of the World Medical Association (Decla-
ration of Helsinki).
Genotyping
Oragene kits were used to extract DNA from saliva sam-
ples. Samples were genotyped using a homogeneous
MassEXTEND (hME) Sequenom assay performed by the
Australian Genome Research Facility. The hME assay is
based on the annealing of an oligonucleotide primer
(hME primer) adjacent to the SNP of interest. The addi-
tion of a DNA polymerase along with a mixture of termi-
nator nucleotides allows extension of the hME primer
through the polymorphic site and generates allele-spe-
cific extension products, each having a unique molecular
mass. The resultant masses of the extension products are
then analysed by matrix-assisted laser desorption/ioniza-
tion time-of-flight mass spectrometry (MALDI-TOF MS)
and a genotype is assigned in real time. The hME assay
was performed in multiplex with up to 36 reactions in a
single well. Genotyping failure rates varied between two
and five percent in the different groups.
Statistical analysis
A Pearson's χ2 test was performed to identify statistical
associations between alleles and genotype and schizo-
phrenia status. Odds ratios (OR) were also calculated.
Tests were performed on both genotype and allele data.
Statistical tests were performed using the COMPARE2
program from the WinPepi suite of epidemiology pro-
grams [29] and SPSS version 16. Hardy-Weinberg equi-
librium (HWE) was computed using Utility Programs for
Analysis of Genetic Linkage [30]. The analysis of geno-
types under a recessive model involved pooling the low-
risk homozygotes and the heterozygotes and comparing
frequencies with the high-risk homozygotes, i.e. OR > 1.
Data were not corrected for multiple testing as only one
SNP was tested in five entirely separate case groups.
Results
In order to investigate the role of the DTNBP1  SNP,
rs9370822, in a range of psychiatric conditions, it was
genotyped in 250 controls, 127 PTSD subjects, 147 nico-
tine dependent subjects, 120 opiate dependent subjects
and 231 alcohol dependent subjects. In addition to our
previously reported association with schizophrenia,
rs9370822 was found to be associated with PTSD, opiate
dependence and nicotine dependence at the allele level
but not with alcohol dependence (Table 1).
At the genotype level, rs9370822 was still associated
with schizophrenia, PTSD, opiate dependence and nico-
tine dependence (Table 2). Individuals with PTSD were
more than three times as likely to carry the CC genotype
compared to the AA genotype. In addition, they were
almost twice as likely to be heterozygous, suggesting a
partially dominant mode of inheritance, ie the heterozy-
gote OR was intermediate between the associated (CC)
and non-associated (AA) genotypes (Table 2). Individuals
with nicotine or opiate dependence were two and a half
Table 1: Allele association of DTNBP1 SNP rs9370822
Sample set χ2 p-value* Odds ratio 95% CI
Schizophrenia† 9.883 0.002 1.61 1.19-2.17
PTSD 12.603 0.0004 1.78 1.28-2.50
Nicotine dependence 7.238 0.007 1.53 1.11-2.13
Opiate dependence 5.143 0.023 1.47 1.04-2.08
Alcohol dependence 1.957 0.162 1.22 0.92-1.61
* p-value determined by Pearson's χ2 test
† previously published data [24]Voisey et al. Behavioral and Brain Functions 2010, 6:41
http://www.behavioralandbrainfunctions.com/content/6/1/41
Page 4 of 7
times as likely to carry the CC genotype compared to the
AA genotype.
Examination of the genotype odds ratios suggests that,
like PTSD, a partially dominant mode of inheritance is
operating for nicotine dependence. However, when com-
pared to the low-risk homozygote, the odds ratio of the
other two genotypes indicated that either a very weak
partially dominant mode of inheritance or, more likely, a
C-allele-recessive pattern of inheritance for schizophre-
nia and opiate dependence was present, i.e. both the
heterozygote OR and the OR for the low-risk homozygote
were approximately one. The rs9370822 SNP was found
to be associated with schizophrenia and opiate depen-
dence when analysed under a recessive model by pooling
genotypes (schizophrenia recessive pattern of inheri-
tance, p = 0.0017, OR = 2.51 95% CI 1.34 to 4.74; opiate
dependence recessive pattern of inheritance, p = 0.014,
OR = 2.22 95% CI 1.10 to 4.46).
Alcohol dependence was not found to be associated
with rs9370822 at the genotype level or under any inheri-
tance model. All sample groups were determined to be in
Hardy-Weinberg equilibrium based on the respective
genotype frequencies of each group (controls, χ2 = 0.007,
p = 0.93; PTSD, χ2 = 0.272, p = 0.60; opiate dependence, χ2
= 2.11, p = 0.15; nicotine dependence, χ2 = 0.64, p = 0.42;
alcohol dependence, χ2 = 0.12, p = 0.73).
Discussion
In order to identify a common molecular mechanism of
disease etiology, DTNBP1  SNP, rs9370822, was chosen
for analysis in a number of psychiatric conditions as we
found it to be significantly associated with schizophrenia
in a previous study [24]. To replicate our findings and
examine the importance of this SNP in psychiatric disor-
ders and potential brain functioning, we analysed a num-
ber of groups including addictive behaviours and anxiety
Table 2: Genotype association of DTNBP1 SNP rs9370822
Sample Set Genotype counts p-value*
AA (%) AC (%) CC (%)
control 113 (47.9) 101 (42.8) 22 (9.3)
Schizophrenia‡ 58 (37.2) 66 (42.3) 32 (20.5) 0.004
0.002†
O d d s  r a t i o 1 . 0 01 . 2 72 . 8 3
p-value 0.57 0.002
PTSD 36 (30) 62 (51.7) 22 (18.3) 0.002
0.0004†
O d d s  r a t i o 1 . 0 01 . 9 33 . 1 4
p-value 0.02 0.00
Nicotine dependence 46 (33.8) 70 (51.5) 20 (14.7) 0.022
0.007†
O d d s  r a t i o 1 . 0 01 . 7 02 . 2 3
p-value 0.04 0.05
Opiate dependence 45 (39.8) 47 (41.6) 21 (18.6) 0.04
0.027†
O d d s  r a t i o 1 . 0 01 . 1 72 . 4 0
p-value 1.00 0.03
Alcohol dependence 92 (41.63) 103 (46.6) 26 (11.76) 0.36
0.16†
O d d s  r a t i o 1 . 0 01 . 2 51 . 4 5
p-value 0.51 0.49
* p-value determined by Pearson's χ2 test
† p-value determined using the extended Mantel-Haenszel test for trend
‡ previously published data [24]Voisey et al. Behavioral and Brain Functions 2010, 6:41
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disorders. In addition to schizophrenia, analysis of
rs9370822 revealed associations with PTSD, opiate
dependence and nicotine dependence at both the allele
and genotype levels. Alcohol dependence was not found
to be associated with rs9370822 in our study but associa-
tion with rs9370822 cannot be ruled out as we only analy-
sed 231 alcohol dependent cases and the p-value was
approaching significance at both the allele and genotype
level (Tables 1 and 2). While a strong effect of DTNBP1
was observed in four clinically distinct phenotypes the
results should be treated with caution as there is a consid-
erable difference in the gender proportions between cases
and controls, for example the PTSD cohort were all male
while 41% of controls were women. Also, because five dif-
fer ent diseases wer e e xamined it is not surprising tha t
there are also differences with regard to age (ranging
from a mean age of 29 years in opiate dependent cases to
52 years in Vietnam veterans with PTSD).
Our schizophrenia study was the first to identify
rs9370822 to be associated with a psychiatric condition
[24]. The position of this SNP is likely to be a region for
high schizophrenia susceptibility as three other SNPs
(rs875462, rs760666 and rs7758659) flank rs9370822 and
have been found to be significantly associated with
schizophrenia [5,31]. We also found two other flanking
SNPs (rs9370823 and rs4236176) to be associated with
schizophrenia in a recent study [24]. Although the
rs9370822 SNP is intronic it is possible that it is a func-
tional SNP that affects RNA splicing or gene transcrip-
tion. It could also be in linkage disequilibrium with a
functional SNP. However a functional polymorphism in a
nearby region that is associated with any psychiatric con-
dition has yet to be identified.
The relationship between abnormal dysbindin function
and addictive and anxiety disorders is unclear. Our find-
ings may indicate that the rs9370822 polymorphism
affects susceptibility to addictive and anxiety disorders by
implication of glutamatergic neurotransmission or the
dopamine system. We previously identified rs9370822 to
follow a recessive pattern of inheritance with respect to
schizophrenia risk [24] which is consistent with the reces-
sive inheritance of dysbindin-1 gene deletion in the
mouse model of schizophrenia [32]. In this study we also
o b s e rv e d  t h a t  o p i a t e  d e pe n d e n c e  a p pe a r ed  t o  f o l l o w  a
recessive pattern of inheritance. However, PTSD and nic-
otine dependence appeared to follow a partially dominant
pattern. Given this, it is possible that rs9370822 results in
a reduction of DTNBP1 function resulting in a recessive
loss-of-function pattern in certain disorders, presumably
because the loss of function from one allele is not suffi-
cient to increase susceptibility to disease detectably but
loss of function of both alleles does. In other disorders a
haploinsufficiency mechanism is operating and results in
a partially dominant mode of inheritance, i.e. loss of func-
tion in one allele increases susceptibility to disease but
not as much as loss of function in both alleles.
It has also been reported that variation in DTNBP1 may
affect the dopamine pathway as dysbindin overexpression
decreases dopamine release and suppression of dysbindin
expression increases dopamine release in the mouse in
vitro [33]. A study has also found that dysbindin defi-
ciency can increase the level of cell surface DRD2 and
enhance DRD2 signalling [34].
Conclusions
The  DTNBP1  pol ym orphism  ide n t ifi ed i n t his  st u dy is
possibly involved in psychiatric liability not only for
schizophrenia but also for addictive and anxiety disor-
ders. It is possible that DTNBP1 variation affects a com-
mon pathway involved in anxiety and addictive disorders.
Whether this pathway involves dopamine or glutamate
signalling or both, remains to be elucidated. As our par-
ticipant numbers are limited our observations should be
viewed with caution until they are independently repli-
cated. However, the associations are unlikely to occur by
chance due to sample size as five separate groups were
analysed (including schizophrenia in a previous study)
and four have been found to be significantly associated
with rs9370822. Although this SNP is intronic, it has been
f o u n d  t o  b e  s t r o n g l y  a s s o c i a t e d  w i t h  s c h i z o p h r e n i a ,
PTSD, opiate and nicotine dependence. Future studies
may explore whether this SNP is functional and what
effect it has on DTNBP1 functioning in the brain.
Our findings are at odds with current knowledge as
these conditions are generally regarded as separate clini-
cal entities. However, our data suggests that these condi-
tions may be different phenotypic expressions of the same
fundamental molecular defect in either the dopamine or
glutamate pathways, or both. Supporting this idea, a
recent review of genome-wide association studies in
schizophrenia [35] suggested that a pleiotropic mecha-
nism may underlie the genetic overlap of schizophrenia
with autism and with bipolar disorder.
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